U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Blood, Vaccines and Other Biologics
  5. Cellular, Tissue, and Gene Therapies Advisory Committee
  6. 2023 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee
  1. Cellular, Tissue, and Gene Therapies Advisory Committee

2023 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee

May 12, 2023

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.

On May 12, 2023, the committee will meet in open session to discuss the Biologics License Application (BLA) 125781 from Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec with the requested indication for the treatment of ambulatory patients with Duchenne Muscular Dystrophy (DMD) with a confirmed mutation in the DMD gene. The meeting will be open to the public.

Back to Top